COMP360 Psilocybin NDA Filed: FDA Review Looms for TRD Therapy

COMPASS Pathways Submits NDA for COMP360 Psilocybin in TRD

COMPASS Pathways announced on November 9, 2026, that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for COMP360, its synthetic psilocybin formulation, as an adjunctive therapy for adults with treatment-resistant depression (TRD). This marks the first time a psilocybin-based therapy has reached this stage in the U.S. regulatory process. The NDA submission signals COMPASS Pathways’ confidence that its clinical trial data, including results from pivotal Phase 3 studies, meet the FDA’s standards for safety and efficacy review. If accepted, the FDA will assign a filing date and may convene an advisory committee to evaluate the application’s merits in public session.

Mechanism, Clinical Evidence, and Regulatory Context

COMP360 is a proprietary, high-purity synthetic psilocybin administered in conjunction with psychological support. The therapy targets adults with TRD, defined as major depressive disorder unresponsive to at least two prior antidepressant treatments. COMPASS Pathways’ Phase 3 program (NCT05552062, among others) enrolled hundreds of participants across multiple countries, using a randomized, double-blind, placebo-controlled design. The primary endpoint was change in depressive symptoms, measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) at fixed timepoints. The NDA includes data on efficacy, safety, and durability of response, as well as adverse event profiles and risk mitigation strategies.

The FDA’s review process for novel psychedelic therapies is uncharted territory. While the agency has previously granted Breakthrough Therapy designation to COMP360 and other psychedelic compounds, no psilocybin-based medicine has yet been approved. The NDA’s acceptance would trigger a standard or priority review clock, typically 10 or 6 months, respectively. The FDA may also convene a Psychopharmacologic Drugs Advisory Committee (PDAC) meeting, where external experts and stakeholders will publicly discuss the risk-benefit profile and regulatory controls.

Policy, Practice, and Industry Implications

An FDA-approved psilocybin therapy for TRD would represent a paradigm shift for U.S. mental health care and drug policy. Approval would move psilocybin from Schedule I status under the Controlled Substances Act for this indication, enabling prescribers to offer the therapy within a regulated medical framework. This would reshape legal risk for clinicians, payers, and health systems, and set a precedent for future psychedelic approvals. The NDA’s progress is being closely watched by federal and state policymakers, as well as insurers and hospital systems, who must plan for new care models and reimbursement pathways.

For the emerging psychedelic industry, FDA approval would validate years of investment in clinical development and regulatory engagement. It would also create a new commercial market for prescription psilocybin, with strict requirements for manufacturing, distribution, and administration. Notably, the NDA’s success or failure will influence the strategies of other companies developing psychedelic therapies for psychiatric and neurological indications.

• Concrete insight: One underappreciated challenge is the FDA’s scrutiny of the psychological support protocol—ensuring standardization and reproducibility of the non-pharmacological component, which is integral to COMP360’s efficacy claims. This requirement could complicate post-approval implementation and reimbursement, as payers may question coverage for the therapy session itself versus the drug product.

Risks, Uncertainties, and Unanswered Questions

The FDA’s decision on COMP360 will hinge on a nuanced risk-benefit analysis. While clinical trials have shown statistically significant reductions in depressive symptoms, questions remain about long-term safety, durability of response, and the risk of adverse psychological events such as suicidal ideation or acute distress. The agency will also consider the potential for off-label use, diversion, and misuse, especially given psilocybin’s Schedule I status outside approved indications.

Another unknown is how the FDA will evaluate the scalability and fidelity of the therapy protocol across diverse clinical settings. The need for trained facilitators, specialized infrastructure, and patient monitoring may limit access and create disparities. Furthermore, the regulatory precedent set by this NDA could shape future approvals for other psychedelics—raising questions about generalizability, comparator arms, and post-marketing surveillance requirements.

What Comes Next: Timelines and Stakeholder Actions

If the FDA accepts the NDA for review, a decision could arrive as early as late 2027, depending on review priority and advisory committee scheduling. Stakeholders—including researchers, health systems, payers, and advocacy groups—should monitor the FDA’s public communications and the Federal Register for advisory committee dates and briefing documents. The outcome will inform not only the future of psilocybin therapy but also the regulatory framework for psychedelic medicine in the U.S.

By Dr. Alex R. Mendel, PhD (Science & Policy Editor). Reviewed by Dr. Jamie Lin, MD (Psychiatry, Clinical Trials), on 2026-11-10. Research based on FDA, ClinicalTrials.gov, and COMPASS Pathways primary sources.